

Company Anicom Holdings, Inc.
Representative Director Nobuaki Komori

(Securities Code: 8715 TSE 1st section)

Inquiries to Tatsuhiko Kamei

Managing Executive Officer

Notice of the status of our activities, February 2020

The following is a summary of the major targets set as the management targets in Anicom Group's pet insurance business and new business initiatives aimed at realizing the vision of becoming a prevention-oriented company.

Notice of the status of our activities, 2019 (From April 1, 2019 to March 31, 2020)


	April	May	June	July	August	September
Net premiums written	3,062 JPYmn (2,707 JPYmn)	3,274 JPYmn (2,890 JPYmn)	3,175 JPYmn (2,777 JPYmn)	3,108 JPYmn (2,737 JPYmn)	3,188 JPYmn (2,790 JPYmn)	3,235 JPYmn (2,792 JPYmn)
(previous year)	(2,707 JP (11111)	(2,890) [111111]	(2,777 JP (11111)	(2,/3/ JPfillil)	(2,790 JP11111)	(2,792 JP11111)
No. of applicants of						
Doubutsu Kenkatsu	4,725	6,580	6,455	6,601	7,492	7,644
(gut microbiota testing)	(-)	(-)	(-)	(-)	(-)	(-)
(previous year)						
No. of samples for						
genetic testing	9,088	10,857	11,463	13,234	16,174	11,945
(previous year)	(-)	(-)	(-)	(-)	(-)	(-)

	October	November	December	January	February	March
Net premiums written*	3,302 JPYmn	3,230 JPYmn	3,303 JPYmn	3,430 JPYmn	3,296 JPYmn	JPYmn
(previous year)	(2,854 JPYmn)	(2,780 JPYmn)	(2,991 JPYmn)	(3,100 JPYmn)	(2,954 JPYmn)	(3,158 JPYmn)
No. of applicants of						
Doubutsu Kenkatsu	9,262	8,657	8,427	9,581	10,719	
(gut microbiota testing)	(-)	(-)	(857)	(5,256)	(4,926)	(5,146)
(previous year)						
No. of samples for						
genetic testing	13,399	15,703	13,140	14,729	9,934	
(previous year)	(-)	(-)	(-)	(517)	(2,014)	(5,211)


^{*}The impact of net premiums written from December 2019 was limited compared to the previous year. It is because one year has passed since the price increase following the product revision implemented in December 2018. However, the impact has been generally as expected.

(Reference) "Notice of the status of our activities" will be disclosed in the middle of each month, but it will be disclosed on the same day as the quarterly earnings announcement date for June, September, December and March.

Net premiums written




No. of applicants of Doubutsu Kenkatsu (gut microbiota testing)



^{*}Started in December 2018

No. of samples for genetic testing



^{*}Started full-scale development in January 2019